Canasa Articles
Shire’s fourth-quarter 2009 earnings significantly beat expectations
22 February 2010
Shire’s new drugs offset slumping Adderall in 3rd quarter 2009
2 November 2009
Japan’s Zeria buys Swiss firm Tillotts for $128 million
14 September 2009
Salix' Apriso shows strong safety data at DDW
3 June 2009
Shire sales up 20% pre-Adderall demise
1 May 2009
Cosmo's 2008 profit jumps 5.2% to $12.9M
30 March 2009
Stock Commentary - New York week to Dec 15, 2008
22 December 2008
Ferring is Auxilium's new EU partner for Testim
8 December 2008
PharmaZell opens Indian mesalamine facility
24 November 2008
Salix receives US appro for Apriso in UC
17 November 2008
3rd-qtr new product sales deliver for Shire, but the firm posts earnings drop on charges
10 November 2008
Shire's Lialda shows sustained 5-ASA release
13 October 2008
Cosmo's first-half 2008 results beat forecasts
11 August 2008
Salix swings to loss in 1st-qtr 2008
19 May 2008
Shire signs US co-promotion deal with TAP for Lialda
31 March 2008
SMC approves Shire's Mezavant XL for UC
24 March 2008
Cosmo's 2007 profit beats estimates
10 March 2008
P&G's Asacol launched in UK for UC
18 February 2008
Salix files for gran mesalamine appro in USA
7 January 2008
P&G reports strong UC data on Asacol
17 December 2007
Axcan agrees to $1.3B private equity buy-out
10 December 2007
First patients recruited into trial of P&G's Asacol
3 December 2007
Shire posts "best ever" results
12 November 2007
P&G's 800mg Asacol MR cleared in UK for acute UC and Crohn
15 October 2007
Cosmo's 1st-half loss up 325% on R&D costs
13 August 2007
Shire's 1st-qtr income soars 85% on sales
7 May 2007
Shire debuts Lialda in USA
26 March 2007
Shire's 2006 income hits $278M, sales up 16%
26 February 2007
Cosmo seeks listing on SWX exchange
19 February 2007
Shire's Lialda cleared by US FDA
22 January 2007
Asacol improves quality of life for UC patients
11 December 2006
S-P and Teva sign UK Mesren promotion deal
13 November 2006
Shire's net income improves 75% in 1st qtr
8 May 2006
Salix progresses patient enrollment
16 January 2006
Shire submits UC NDA on Mesavance
9 January 2006
Shire announces 13% growth in revenue
7 March 2005
Axcan's 1-gram mesalamine suppository gets OK
15 November 2004
Procter & Gamble's 1st-qtr EPS climbs 16%
1 November 2004
Shire raises forecasts on good 2nd-qtr
9 August 2004
Genzyme grants P&G exclusive RDP58 licence
12 April 2004
Strong performace for Shire in 2003
22 March 2004
Adderall drives growth at Shire in 1st quarter
12 May 2003
Shire's profits up on switching strategy
3 March 2003
Shire
12 August 2002
Revenues in 1st-qtr rise 30% at Shire
6 May 2002
Shire earnings jump 54% for third quarter
7 November 2001
Axcan Pharma launches Canasa in USA
20 April 2001
Analysts expectant on future prospects for Canada's Axcan Pharma
13 February 2001
Shire 3rd-qtr pretax profits leap 67%
2 November 2000
Good growth at Shire, Reminyl gets FDA boost
3 August 2000
Shire's pretax profits climb 40% in 1st qtr
26 April 2000
Merger with Roberts going smoothly at Shire as revenues rise 30%
29 February 2000
US Third-Quarter Results In Brief
4 November 1998
Salix Pharmaceuticals receives R&D funding from Astra
29 October 1998
Roberts Pharma Beats Analysts' Expectations
22 July 1998
P&G's Asacol Cleared In USA
28 August 1997
Yamanouchi Looks To New Products For Growth
23 October 1995
....And Marion Merrell Dow Updates On R&D Efforts
10 April 1995
YAMANOUCHI LAUNCHES PENTASA
21 March 1994
NISSHIN FLOUR MILLING CHANGES DIRECTION
20 December 1993
PENTASA APPROVED IN USA FOR MARKETING
17 May 1993
SOLVAY AND KABI AGREEMENT
9 November 1992
Showing 1-82 of 82 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
